Zacks: Brokerages Anticipate SI-Bone Inc (NASDAQ:SIBN) Will Announce Earnings of -$0.32 Per Share

Equities analysts expect SI-Bone Inc (NASDAQ:SIBN) to report earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for SI-Bone’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.34). SI-Bone reported earnings of ($0.22) per share in the same quarter last year, which would indicate a negative year over year growth rate of 45.5%. The company is expected to report its next earnings results on Thursday, March 5th.

According to Zacks, analysts expect that SI-Bone will report full-year earnings of ($1.51) per share for the current financial year, with EPS estimates ranging from ($1.53) to ($1.49). For the next year, analysts forecast that the company will report earnings of ($1.12) per share, with EPS estimates ranging from ($1.41) to ($0.83). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover SI-Bone.

SI-Bone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.10). SI-Bone had a negative return on equity of 42.29% and a negative net margin of 54.85%. The business had revenue of $16.18 million during the quarter.

Several research firms have commented on SIBN. Zacks Investment Research lowered shares of SI-Bone from a “hold” rating to a “sell” rating in a report on Friday, November 15th. ValuEngine lowered shares of SI-Bone from a “buy” rating to a “hold” rating in a report on Saturday, December 7th.

SIBN stock traded up $0.64 during mid-day trading on Friday, hitting $19.70. The stock had a trading volume of 415,381 shares, compared to its average volume of 95,716. The company has a current ratio of 8.78, a quick ratio of 8.40 and a debt-to-equity ratio of 0.57. SI-Bone has a 52 week low of $14.08 and a 52 week high of $23.03. The firm has a market capitalization of $460.10 million, a P/E ratio of -27.75 and a beta of -0.58. The firm has a fifty day simple moving average of $17.69 and a 200 day simple moving average of $18.21.

In other SI-Bone news, CEO Jeffrey W. Dunn sold 7,250 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $16.03, for a total value of $116,217.50. Also, CMO W Carlton Reckling sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Over the last three months, insiders sold 106,492 shares of company stock worth $1,915,993. Insiders own 38.80% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in SIBN. BlackRock Inc. grew its holdings in shares of SI-Bone by 70.7% during the 2nd quarter. BlackRock Inc. now owns 1,120,294 shares of the company’s stock valued at $22,787,000 after purchasing an additional 463,874 shares during the last quarter. Gilder Gagnon Howe & Co. LLC grew its holdings in shares of SI-Bone by 153.8% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,087,766 shares of the company’s stock valued at $19,221,000 after purchasing an additional 659,133 shares during the last quarter. First Light Asset Management LLC bought a new stake in shares of SI-Bone during the 2nd quarter valued at approximately $13,248,000. Vanguard Group Inc. grew its holdings in shares of SI-Bone by 65.5% during the 2nd quarter. Vanguard Group Inc. now owns 563,111 shares of the company’s stock valued at $11,454,000 after purchasing an additional 222,788 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of SI-Bone by 4.0% during the 2nd quarter. Wells Fargo & Company MN now owns 465,846 shares of the company’s stock valued at $9,475,000 after purchasing an additional 18,030 shares during the last quarter. 51.00% of the stock is currently owned by hedge funds and other institutional investors.

About SI-Bone

SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Further Reading: What is the Russell 2000 Index?

Get a free copy of the Zacks research report on SI-Bone (SIBN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.